Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to H

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clin

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.

Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX d

HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy

Markets stayed fearful as index fell to 38; Dow gained, S&P/Nasdaq slipped amid oil surge and Ir

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announ

Jefferies analyst Glen Santangelo downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold an

Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday&#39

PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand

PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value

U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo be

Options traders are taking a bearish stance on two stocks attracting unusual volume today: Pacira Bi

U.S. stocks fell, while Helen of Troy jumped 15.5% on strong earnings and raised guidance. Pacira so

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Pacira BioSciences, Inc.

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expand

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and

Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and

Caregivers say they need clearer pain management plans, earlier education, and practical support on

Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, wit

– Expands patient access to opioid-sparing pain control and advances 5x30 strategy –  BRISBANE, Cali

Bank of America Corp DE bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) d

Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Ou

Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with

BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the in

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the ind

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerat

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerat

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and por

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estim

Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.73 per share which beat the analy

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing

With drug product from the new manufacturing process now available, the first patient has been enrol

HC Wainwright & Co. analyst Douglas Tsao reiterates Pacira BioSciences (NASDAQ:PCRX) with a B

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- B

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative

Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewe

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perfor

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and raises t

Pacira BioSciences, Inc.___________________________ Summary of 2026 Financial Guidance(dollars in mi

Pacira BioSciences (NASDAQ:PCRX) reported quarterly earnings of $0.60 per share which beat the analy